CymaBay

CymaBay was a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases. The company, formerly listed on NASDAQ with ticker symbol CBAY, was acquired by Gilead Sciences in 2024. This followed the successful outcome of a pivotal Phase 3 trial of its lead asset, seladelpar, a first-in-class oral, selective PPARδ agonist, as a treatment for patients with primary biliary cholangitis (PBC). Seladelpar was subsequently approved by regulatory authorities in the US (as Livdelzi®), and in the EU and UK (as Lyvdelzi®).